Year-End Report 23/24

September 2023 – August 2024, Diamyd Medical AB (publ), Fiscal year 2023/2024Precision Medicine for Autoimmune DiabetesAiming for Accelerated Market Approval Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com September 1, 2023 – August 31, 2024 · Net result: MSEK -151.8 (-116.1), fourth quarter: MSEK -49.7 (-37.5). The higher costs compared to previous year is mainly due to that all 60 clinics in Europe and U.S. in the Phase III trial DIAGNODE-3 are activated and recruiting